Rhinomed Limited (RHNMF) Research

Headquartered in Cremorne, Australia, Rhinomed Limited, founded in 2004, is a global innovator specializing in the research, development, and commercialization of consumer and medical devices. The company's core expertise lies in wearable nasal technologies engineered to improve breathing, enhance sleep quality, promote general health, and aid in disease diagnosis. Their product portfolio features Turbine, designed to optimize breathing for athletes; Mute, assisting users to breathe more freely and reduce snoring; Pronto, a vapor inhaler for enhanced airflow and improved sleep; and Rhinoswab, utilized for nasal swab collection. Beyond these offerings, Rhinomed is actively pursuing advancements in diverse areas, such as sleep patterns and architecture, the interplay between sleep, respiratory function, and cognitive health, obstructive sleep apnea, pain management, nausea relief, respiratory illnesses, and advanced diagnostics and sensing. They additionally provide a specialized drug delivery platform for cannabinoid-based formulations. The company previously operated as Consegna Group Limited before rebranding to Rhinomed Limited in November 2013.

Open Rhinomed Limited (RHNMF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.